T-cell receptor (TCR) on CD8-positive T-lymphocyte (TCR (on CD8+ T cell); sometimes abbreviated as TCR-CD8, but generally "TCR" suffices in context)

The T-cell receptor (TCR) on CD8-positive T-lymphocyte is a multi-subunit, membrane-bound protein complex predominantly composed of a heterodimer of α and β chains, each featuring variable and constant regions that interact with peptides presented in the context of major histocompatibility complex class I (MHC-I) molecules on the surface of nucleated cells. The TCR is non-covalently associated with the CD3 complex and additional signaling molecules, including the co-receptor CD8, which acts as an essential mediator for MHC-I binding and signal initiation. Upon recognition of antigen–MHC-I complexes, the TCR transduces activation signals through ITAM-containing CD3 subunits, culminating in the activation, proliferation, and cytotoxic differentiation of the CD8+ T cell, which can then eliminate infected, cancerous, or otherwise "altered self" cells through mechanisms such as perforin/granzyme-mediated lysis or Fas–Fas ligand interactions. The TCR repertoire is extraordinarily diverse, generated by V(D)J recombination during T-cell development, enabling recognition of a vast array of antigens. CD8+ T cells and their TCRs are central to adaptive immune surveillance, anti-viral and anti-tumor responses, and remain a principal focus of immunotherapeutic approaches including immune checkpoint blockade and engineered TCR or CAR-T cell therapies.

Other names

TCR (T-cell receptor)TCRαβ (for the predominant αβ heterodimer form)T-cell antigen receptorCytotoxic T-cell receptor

Enhancement of TCR signaling (checkpoint blockade removes inhibition on TCR-mediated activation); Adoptive transfer augments antigen specificity by engineering TCRs or CARs with desired peptide–MHC specificity; Immunosuppressive agents may cause TCR+ cell depletion